Sweet syndrome is a rare, inflammatory, non-infectious skin disorder characterized by an acute onset of skin leasions such as painful, erythematous plaques, nodules and papules, most frequently located on the upper extremities, trunk, neck and face. Generally, dermatological symptoms are accompanied by fever, headaches, arthralgia and leukocytosis. The syndrome belongs to the group of febrile neutrophilic dermatoses. Skin biopsy reveals a diffuse, neutrophilic infiltrate in the upper dermis. Sweet syndrome presents in three clinical subtypes: classical, malignancy-associated and drug-induced. The etiology of this disease still remains unclear, but it seems that can be associated with dysfunction of the immune system, genetic predispostion and neoplastic process. Sweet syndrome has been reported in relation to pregnancy, drug administration, vaccinaton and infection of the respiratory or digestive system. Systemic glucocorticosteroids still remain the first line treatment for most patients, nevertheless new therapeutic options against reccurent Sweet syndrome have been investigated.

Clinical depression is a psychiatric disorder characterized by symptoms such as loss of interest and pleasure from typically enjoyable activities (anhedonia), pervasive low mood, and diminished energy leading to excessive fatigue and lower activity which have been present in a patient for at least two weeks. Available therapies consist primarily of pharmacological intervention. Indeed, some groups of medications such as SSRIs, SNRIs, TCA’s and tetracyclic antidepressants have been used to treat depression for decades, frequently in combinations. An example of such a combination is “California Rocket Fuel” composed of venlafaxine and mirtazapine   Objective:   To review the current literature on the efficacy of the combination of venlafaxine and mirtazapine in treating clinical depression both in drug-resistant depression and as a first-line option. To explore the risks and benefits of this choice of therapy and discuss its potential mechanism of action.   Methods:   Literature review of Pubmed, Google Scholar, Science Direct, and available medical textbooks.   Conclusions: Treatment with venlafaxine and mirtazapine is safe, especially for drug-resistant depression. It is worth considering adding venlafaxine to already ongoing pharmacotherapy with mirtazapine when the patient experiences sleepiness and the symptoms of depression have not been sufficiently reduced. Augmenting venlafaxine treatment with mirtazapine also seems necessary when the patient complains of insomnia. One may consider implementing such therapy as a first-line treatment in patients who suffer from depression for a long time and experience insomnia in its course.

Mental disorders are a significant clinical problem due to the frequent ineffectiveness of their treatment. This is due to the not fully understood etiopathogenesis of these diseases. Often, the mechanism of action of a given therapy is not known and it is not clear why treatments that work in some patients may not produce any clinical improvement in others. The currently used pharmacotherapy and psychotherapy often turn out to be insufficient, which prompts the search for other methods of therapy, including neurosurgical methods. The currently carried out attempts at neurosurgical treatment of mental disorders differ greatly in terms of precision and surgical technique from the controversial procedures from the middle of the last century. Ablative methods and deep brain stimulation, which has been increasingly used in recent years,

Oncofertility is an emerging field at the intersection of oncology and reproductive medicine that aims to address the fertility-related consequences of cancer treatment. Advances in cancer diagnosis and treatment have led to significant improvements in survival rates, but many cancer treatments can cause infertility or premature ovarian failure, which can have a profound impact on the quality of life and overall well-being of cancer survivors. Oncofertility seeks to provide patients with the opportunity to preserve their reproductive potential before undergoing cancer treatment, thus ensuring that they have options for starting a family after treatment. This field encompasses a range of approaches, including fertility preservation techniques. While oncofertility is still a relatively new field, it has already made significant strides in improving the quality of life for cancer survivors. However, there are still many challenges that must be addressed, including access to oncofertility services and the development of new and more effective techniques. This paper will explore the current state of oncofertility research and highlight some of the key challenges and opportunities in this important field.

The dominant approach in the fight against breast cancer is mastectomy. Surgical operations include diagnostic, therapeutic, palliative and reconstructive procedures. The decision as to the procedure depends on the type, location and advancement of the tumor, as well as on the preferences of the patients, the skills of the operator and the availability of methods at a given centre. It is worth noting that with the increasing number of patients, there have also been significant advances in treatment, the surgical techniques used, and consequently the quality of life index has also increased. Nowadays, clinicians' attention is focused not only on the elimination of the cancer, but also on the best possible cosmetic effect of the treatment. In breast cancer, the approach to the patient should be multidisciplinary, because mastectomy and its complications affect the patient's appearance after surgery, as well as psychological aspects, changing self-perception and pain complaints.